Kala Pharmaceuticals, Inc. (KALA) Stock Forecast
KALA analyst forecast
as of October 18, 2026- Analyst consensus
- —
- Price target
- $1.50 average of analyst targets
- Upside to target
- +689.9% from the latest close
- Next earnings
- November 18, 2026
- 52-week range
- $0.19 – $66.50
KALA price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
KALA earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$0.53 | −$0.53 | −$0.53 | −$4.45 | +88.1% | 1 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
KALA revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Next fiscal year (2026) | $0 | $0 | $0 | 0.0% | 1 |
KALA EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
KALA EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Next fiscal year (2026) | −$3.32 | −$3.35 | −$4.36 | −$2.55 | −$0.53 | −84.0% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
KALA earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; KALA beat in 7 of 10.
What analysts expect from KALA
The average price target is $1.50, 689.9% above the latest close of $0.19. For 2026 the average estimate is −$0.53 per share. Kala Pharmaceuticals beat the EPS estimate in 7 of the last 10 quarters.
Related: KALA income statement, KALA key metrics, KALA chart. See the KALA stock overview for the latest quote and news.
KALA forecast FAQ
What is Kala Pharmaceuticals's price target?
The average analyst price target for Kala Pharmaceuticals is $1.50, 689.9% above the latest close of $0.19.
When does Kala Pharmaceuticals report earnings?
Kala Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 18, 2026.
Does Kala Pharmaceuticals usually beat earnings estimates?
Kala Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 10 quarters.